ArticleBiomedicines2026
Biomarkers of Inflammaging and Cellular Senescence in Musculoskeletal (MSK) Diseases: The Knowns and the Unknowns.
Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancing age, while a natural trajectory, often leads to several age-related diseases (ARDs) and impacts the quality of life (QOL) of the elderly. The World Health Organization (WHO) predicts that the incidence of ARDs is only going to increase over the next couple of decades. Musculoskeletal (MSK) diseases associated with advancing age are a major global health burden and are closely associated with cellular senescence, inflammaging and immunosenescence. To target these, a clear pathway with well-defined biomarkers that can then be translated into clinical applications is needed. Clearly defined biomarkers will bring us one step closer to dissecting age-related MSK changes, tracking these changes with advancing age, predicting these MSK ARDs and thus providing a platform towards healthy aging, disease-free life in the elderly and longevity. This review outlines our current knowledge in the field, discusses the current knowns and unknowns, provides an overview of the anti-aging strategies, and finally encourages its readers to consider approaches to help converge biomarkers of aging for clinical translation using next-generation technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.